what is the efficacy mometasonefuroate nasal spray withallergic rhinitis patient and is it safe ? (Tertiary information :micromedex) Mometasonefuroate FDA Labeled Indication a) Overview FDA Approval: Adult (nasal spray only), Pediatric (nasal spray only, 2 years and older) Efficacy: Adult ,Pediatric Recommendation: Adult, Class IIa; Pediatric, Class IIa Strength of Evidence: Adult, Category B; Pediatric, Category B b) Summary: Mometasonefuroate nasal spray is indicated for the treatment of nasal symptoms associated with seasonal allergic rhinitis and perennial allergic rhinitis in adults and children 2 years and older. Contraindication 1) hypersensitivity to mometasonefuroate or any other component of the product 2) known hypersensitivity to milk proteins (oral inhalation) 3) primary treatment of status asthmaticus or other acute episodes of asthma requiring intensive intervention (oral inhalation) Adverse reaction Common Gastrointestinal: Abdominal pain ,Indigestion, Nausea Musculoskeletal: Backache, Musculoskeletal pain, Myalgia Neurologic: Headache Reproductive: Dysmenorrhea Respiratory: Allergic rhinitis, Candidiasis, Epistaxis, Pharyngitis, Upper respiratory infection Serious Endocrine metabolic: Secondary hypocortisolism Immunologic: Anaphylaxis Other: Angioedema Monitoring Parameter 1) Therapeutic Perennial Allergic Rhinitis and Seasonal Allergic Rhinitis :Improvement in nasal symptoms associated with indicative of efficacy. 2) Toxic a) Laboratory Parameters Topical :Periodically evaluate for hypothalamic-pituitary-adrenal (HPA) axis suppression (using adrenocorticotrophic hormone (ACTH) stimulation, A.M. plasma cortisol, and urinary-free cortisol tests) in patients applying mometasonefuroate to occluded or large surface areas b) Physical Findings Nasal Spray and Oral Inhalation o Routinely monitor growth (using stadiometry) in pediatric patients treated with mometasone o Closely monitor patients with a history of increased intraocular pressure, glaucoma and/or cataracts during treatment . Nasal Spray o Periodically examine patients on long-term (several months or longer) mometasonefuroate nasal spray therapy for changes in nasal mucosa .